HomeCompanies › CLRB

Cellectar Biosciences, Inc.

Pipeline (11 active programs)

CLR 121125

  • Undisclosed indication

Technology platforms

PDC

Phospholipid drug conjugate (PDC) / phospholipid ether drug conjugate delivery platform that specifically targets cancer cells; enables radioconjugate programs (phospholipid radioconjugates, PRCs) designed to deliver radioisotopes directly to cancer cells while limiting exposure to healthy cells; focus area: oncology

Biotech Distilled coverage (1)

Articles open on Substack. Some deep dives are subscriber-only.